神经调控对多种精神障碍的疗效:208项随机对照试验的系统综述与Meta分析
该研究基于208项随机对照试验,采用随机效应Meta分析评估经颅磁刺激(TMS)和经颅直流电刺激(tDCS)相比伪刺激对多种精神障碍核心症状及认知功能的疗效。结果显示TMS对广泛性焦虑障碍、强迫症、单相抑郁症状及tDCS对物质使用障碍症状有显著改善,tDCS对精神分裂症注意和工作记忆有显著改善。
要点
- TMS对广泛性焦虑障碍症状的效应量SMD=-1.8(95%CI:-2.6至-1),无显著异质性。
- tDCS对物质使用障碍症状的效应量SMD=-0.73(95%CI:-1.00至-0.46)。
- tDCS对精神分裂症注意和工作记忆有显著改善,效应量分别为SMD=-0.3和-0.38。
核心结论
- TMS和tDCS可使多种精神障碍患者获益,显著改善临床维度,包括对药物治疗反应不佳的精神分裂症认知缺陷。
研究设计与样本
- 系统综述与随机效应Meta分析,基于系统综述识别的208项随机对照试验,比较神经调控(TMS或tDCS)与伪刺激对多种精神障碍核心症状和认知功能的疗效。
主要发现
- TMS对广泛性焦虑障碍症状有显著效应,SMD=-1.8(95%CI:-2.6至-1),无显著异质性。
- tDCS对物质使用障碍症状有显著效应,SMD=-0.73(95%CI:-1.00至-0.46)。
- TMS对强迫症症状有显著效应,SMD=-0.66(95%CI:-0.91至-0.41),但存在显著异质性。
- TMS对单相抑郁症状有显著效应,SMD=-0.60(95%CI:-0.78至-0.42),但存在显著异质性。
- 基于刺激部位和治疗次数的亚组分析显示,特定TMS刺激方案有阳性效应且无显著异质性。
关键数值与推荐
- TMS对广泛性焦虑障碍症状:SMD=-1.8(95%CI:-2.6至-1),无显著异质性。
- tDCS对物质使用障碍症状:SMD=-0.73(95%CI:-1.00至-0.46)。
- TMS对强迫症症状:SMD=-0.66(95%CI:-0.91至-0.41),存在显著异质性。
- TMS对单相抑郁症状:SMD=-0.60(95%CI:-0.78至-0.42),存在显著异质性。
- tDCS对精神分裂症注意:SMD=-0.3(95%CI:-0.55至-0.05),无显著异质性;工作记忆:SMD=-0.38(95%CI:-0.74至-0.03),无显著异质性。
临床怎么用
- 作者认为TMS和tDCS可使多种精神障碍患者获益,显著改善临床维度,包括对药物治疗反应不佳的精神分裂症认知缺陷。
局限性
- TMS对强迫症和单相抑郁症状的效应存在显著异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-invasive brain stimulation (NIBS), including transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS), is a potentially effective treatment strategy for a number of mental conditions. However, no quantitative evidence synthesis of randomized controlled trials (RCTs) of TMS or tDCS using the same criteria including several mental conditions is available. Based on 208 RCTs identified in a systematic review, we conducted a series of random effects meta-analyses to assess the efficacy of NIBS, compared to sham, for core symptoms and cognitive functioning within a broad range of mental conditions. Outcomes included changes in core symptom severity and cognitive functioning from pre- to post-treatment. We found significant positive effects for several outcomes without significant heterogeneity including TMS for symptoms of generalized anxiety disorder (SMD = -1.8 (95% CI: -2.6 to -1), and tDCS for symptoms of substance use disorder (-0.73, -1.00 to -0.46). There was also significant effects for TMS in obsessive-compulsive disorder (-0.66, -0.91 to -0.41) and unipolar depression symptoms (-0.60, -0.78 to -0.42) but with significant heterogeneity. However, subgroup analyses based on stimulation site and number of treatment sessions revealed evidence of positive effects, without significant heterogeneity, for specific TMS stimulation protocols. For neurocognitive outcomes, there was only significant evidence, without significant heterogeneity, for tDCS for improving attention (-0.3, -0.55 to -0.05) and working memory (-0.38, -0.74 to -0.03) in individuals with schizophrenia. We concluded that TMS and tDCS can benefit individuals with a variety of mental conditions, significantly improving clinical dimensions, including cognitive deficits in schizophrenia which are poorly responsive to pharmacotherapy.
引用
- Hyde J, Carr H, Kelley N, et al. Efficacy of neurostimulation across mental disorders: systematic review and meta-analysis of 208 randomized controlled trials. Mol Psychiatry. 2022. PMID: 35365806. doi:10.1038/s41380-022-01524-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。